It has been a while since the latest market update from Regeneus, so I thought I'd do some reading to try and determine what these future updates might entail.
The Center for Veterinary Biologics at the US Department of Agriculture recently gave Regeneus the green light to commercialise it's unique cancer vaccine for dogs.
Some excerpts from a recent Proactive Investors article.
'...the vaccine has been through pre-clinical testing at the Kolling Institute in Sydney which demonstrated that it could induce remission or significantly slow tumour growth in an aggressive glioma animal model.'
'Regeneus holds an exclusive worldwide licence for commercialisation of the technology for veterinary applications - and an option over all human applications as well'
"I'm confident that we'll see positive results from the controlled study planned for early next year."
'The success of the vaccine to date in a variety of hard to treat cancers in dogs bodes well for a clinical study of the vaccine for human cancer in the near future."
"The next step is to finalise the planning and initiate our US based marketing study which will generate important data to support the commercialisation of the cancer vaccine. The study is scheduled to commence in early 2014,"
It would seem that Regeneus are soon to commence the planning of the commercialisation their canine cancer vaccine in the US. Could this be their next announcement? Perhaps. Looking forward to the next release either way.
RGS Price at posting:
49.0¢ Sentiment: Buy Disclosure: Held
